Mitral leaflet in functional regurgitation: passive bystander or active player?

In a population-based study, mitral regurgitation (MR) has been found to be the most common form of valvular heart disease in the United States.1 The incidence of MR rises sharply at ≈65 years of age: moderate or severe MR is estimated to occur in 1% of the 55 to 64 age group, increasing to 6.4% for individuals aged 65 to 74 and to 9.3% for those older than 75.1 In view of the increasing life expectancy of the general population, we can anticipate encountering a substantial rise in the number of patients with hemodynamically significant MR. Because heart failure, ischemic heart disease, and other disorders affecting the left ventricle become more prevalent with older age, one can speculate that it is particularly functional MR that will contribute to the overall increase in MR cases, with the numbers caused by degenerative disease rising less dramatically with age. Article see p 334 As the rate of rheumatic disease has decreased dramatically in the Western world, degenerative disease, largely resulting from myxomatous degeneration, constitutes the most common reason for mitral valve surgery. The true incidence of functional MR, in which the primary cause of regurgitation does not originate from the leaflets themselves, is not well known. Many patients with functional MR never undergo surgery, and the disease can remain silent for some time or can be masked by the underlying pathology of the left ventricle and the coronary arteries. Functional MR is an entity that was poorly understood until some years ago. Whereas it was believed that in the setting of ischemic heart disease, MR is often caused by “papillary muscle dysfunction,”2 we now know that in the absence of rupture, isolated ischemia or even infarction of a papillary muscle rarely causes regurgitation3 unless accompanied by displacement of the …

[1]  F. Schoen,et al.  Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. , 2001, The American journal of pathology.

[2]  E. Schwammenthal,et al.  Integrated mechanism for functional mitral regurgitation: leaflet restriction versus coapting force: in vitro studies. , 1996, Circulation.

[3]  R R Markwald,et al.  Embryonic endothelial cells transdifferentiate into mesenchymal cells expressing smooth muscle actins in vivo and in vitro. , 1997, Circulation research.

[4]  G. Gensini,et al.  Insights on left ventricular and valvular mechanisms of recurrent ischemic mitral regurgitation after restrictive annuloplasty and coronary artery bypass grafting. , 2008, The Journal of thoracic and cardiovascular surgery.

[5]  P. McCarthy,et al.  Mitral valve stiffening in end-stage heart failure: evidence of an organic contribution to functional mitral regurgitation. , 2005, The Journal of thoracic and cardiovascular surgery.

[6]  B. Griffin,et al.  Apparently normal mitral valves in patients with heart failure demonstrate biochemical and structural derangements: an extracellular matrix and echocardiographic study. , 2005, Journal of the American College of Cardiology.

[7]  A. Mittal,et al.  Combined Papillary Muscle and Left Ventricular Wall Dysfunction as a Cause of Mitral Regurgitation: An Experimental Study , 1971, Circulation.

[8]  Robert A Levine,et al.  Mitral Leaflet Adaptation to Ventricular Remodeling: Occurrence and Adequacy in Patients With Functional Mitral Regurgitation , 2008, Circulation.

[9]  R. Suri Mechanisms of Recurrent Functional Mitral Regurgitation After Mitral Valve Repair in Nonischemic Dilated Cardiomyopathy: Importance of Distal Anterior Leaflet Tethering , 2010 .

[10]  T. Koshiji,et al.  [Syndrome of papillary muscle dysfunction]. , 1996, Ryoikibetsu shokogun shirizu.

[11]  Anthony Atala,et al.  Stretch and Growth: The Molecular and Physiologic Influences of Tissue Expansion , 2002, Plastic and reconstructive surgery.

[12]  E. Grossi,et al.  Mitral valve surgery in heart failure: insights from the Acorn clinical trial. , 2006, The Journal of thoracic and cardiovascular surgery.

[13]  H. Eisen,et al.  Surgical ventricular reconstruction for heart failure. , 2009, The New England journal of medicine.

[14]  J B Seward,et al.  Determinants of the Degree of Functional Mitral Regurgitation in Patients With Systolic Left Ventricular Dysfunction: A Quantitative Clinical Study , 2000, Circulation.

[15]  J. Gardin,et al.  Burden of valvular heart diseases: a population-based study , 2006, The Lancet.

[16]  R. P. Cochran,et al.  Stress/Strain Characteristics of Porcine Mitral Valve Tissue: Parallel Versus Perpendicular Collagen Orientation , 1992, Journal of cardiac surgery.

[17]  Jeroen J. Bax,et al.  Mechanism of improvement in mitral regurgitation after cardiac resynchronization therapy. , 2008, European heart journal.

[18]  M. Frid,et al.  Mature Vascular Endothelium Can Give Rise to Smooth Muscle Cells via Endothelial-Mesenchymal Transdifferentiation: In Vitro Analysis , 2002, Circulation research.

[19]  Hani N Sabbah,et al.  Mitral valve surgery in heart failure: insights from the Acorn Clinical Trial. , 2006, The Journal of thoracic and cardiovascular surgery.

[20]  Paul Dagum,et al.  Mitral Leaflet Remodeling in Dilated Cardiomyopathy , 2006, Circulation.

[21]  Christopher M O'Connor,et al.  Coronary bypass surgery with or without surgical ventricular reconstruction. , 2009, The New England journal of medicine.

[22]  F. Schoen,et al.  Aortic Valve Endothelial Cells Undergo Transforming Growth Factor-β-Mediated and Non-Transforming Growth Factor-β-Mediated Transdifferentiation in Vitro , 2001 .

[23]  Suzanne Sullivan,et al.  Active Adaptation of the Tethered Mitral Valve: Insights Into a Compensatory Mechanism for Functional Mitral Regurgitation , 2009, Circulation.